Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 72 (RPL23AP72)
- Target
- RPL23AP72
- Molecular classification
- Other (Processed pseudogene)
01
Overview
Ribosomal protein L23a pseudogene 72 (RPL23AP72) is a human processed pseudogene located on chromosome 16; it belongs to the family of ribosomal protein L23a pseudogenes, which are copies of ribosomal protein genes that have lost their protein-coding potential. RPL23AP72 does not appear to encode a protein or have known physiological roles. It has no known direct functional or clinical relevance, nor is it currently established as a therapeutic target. Related ribosomal protein L23a pseudogenes have been implicated in cancer prognosis research, but there are no data demonstrating such a role for RPL23AP72 itself. RPL23AP72 is a processed pseudogene, not a functional protein or therapeutic target. No direct biological function, disease mechanism, clinical biomarker utility, or druggability is established for RPL23AP72. The gene is properly named and catalogued, but does not fulfill the criteria of a therapeutic or classical drug target.
- Other names
- RPL23A_30_1480RPL23AP72
02
Mechanism of action
None. No drugs target this pseudogene
03
Biological functions
Other / Not established. Pseudogenes like RPL23AP72 typically do not encode proteins and have no verified biological function, but some ribosomal protein pseudogenes may have regulatory roles (e.g., acting as molecular sponges for miRNAs), although this has not been functionally validated for RPL23AP72
04
Disease associations
Other / Not established. There is no established direct disease association for RPL23AP72; evidence for related pseudogenes (e.g., RPL23AP53) suggests potential roles in gene regulation and prognosis biomarkers in specific cancers, but this is not proven for RPL23AP72 itself
05
Safety considerations
None. No therapeutic interventions are directed against this pseudogene
06
Interacting drugs
None known. As a pseudogene, RPL23AP72 does not produce a protein product, so there are no direct drug interactions
07
Biomarkers
None validated for RPL23AP72 specifically. However, related ribosomal protein L23a pseudogenes (such as RPL23AP53) have been explored as potential prognosis biomarkers in melanoma, suggesting that other family members like RPL23AP72 might be researched in similar contexts in the future
Beyond the preview
Go deeper on Ribosomal protein L23a pseudogene 72 (RPL23AP72).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 72 (RPL23AP72).